Akari Therapeutics PLC (NASDAQ:AKTX) Stock Has Average Target Price of $32.33

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) have received an average rating of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $32.33.

Several equities research analysts recently weighed in on the company. Wall Street Zen raised Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Maxim Group upgraded shares of Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research report on Monday, July 20th. Alliance Global Partners raised shares of Akari Therapeutics to a “strong-buy” rating in a research note on Friday, September 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Akari Therapeutics in a research note on Friday, October 2nd.

Akari Therapeutics Trading Down 7.5%

Shares of AKTX stock traded down $0.66 during midday trading on Friday, hitting $8.18. The company had a trading volume of 21,683 shares, compared to its average volume of 50,568. The company’s 50 day simple moving average is $9.16 and its 200 day simple moving average is $9.16. Akari Therapeutics has a 52-week low of $3.02 and a 52-week high of $33.60.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc (NASDAQ: AKTX) is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on regulating the complement system and inflammatory pathways that contribute to tissue damage.

Akari’s lead investigational product is nomacopan, a recombinant small protein designed to inhibit complement component 5 (C5) and leukotriene B4 (LTB4). The company is also developing a long-acting formulation known as PAS-nomacopan.